Semin Thromb Hemost 2011; 37(8): 897-902
DOI: 10.1055/s-0031-1297368
© Thieme Medical Publishers

Dyslipidemia, Statins, and Venous Thromboembolism

Pavel Poredos1 , Mateja Kaja Jezovnik1
  • 1Department of Vascular Disease, Ljubljana University Medical Centre, Ljubljana, Slovenia
Further Information

Publication History

Publication Date:
23 December 2011 (online)


Venous thromboembolism (VTE) is one of the most frequent and serious vascular diseases. Although the major risk factors of VTE are well recognized, the pathology often develops in subjects without any obvious precipitating factor. Recent evidence suggests a link between arterial and venous thrombosis, particularly in patients with idiopathic venous thrombosis. Therefore, similar or identical risk factors may play a role in the development of both diseases. A positive association between classical risk factors of atherosclerosis, including dyslipidemia, and VTE has been reported. Recent studies demonstrated an association between hypercholesterolemia and objectively verified VTE. Circulating lipids have been shown to have both prothrombotic- and endothelium-deteriorating properties. Studies suggested a greater generation of thrombin, endothelial dysfunction, and higher platelet activity in hyperlipidemic blood. By impeding these mechanisms, statins may protect against VTE. Observational, controlled studies and two meta-analyses showed that statins significantly reduced VTE risk, most likely in a process independent from cholesterol lowering, through mechanisms related to the pleiotropic effects of these drugs. Currently, it is unknown whether VTE prevention is a class-effect of statins, or if statins differ in their antithrombotic efficacy, and it is also unknown if statin benefit is dose-dependent. However, there are also opposite findings about the efficacy of statins in prevention of VTE. Therefore, the use of statins for prophylaxis of VTE cannot be generally recommended at this stage. Further studies are needed to identify those patients who could eventually benefit maximally from treatment with statins for prevention of VTE.


  • 1 Lijfering W M, Flinterman L E, Vandenbroucke J P, Rosend F R, Cannegieter S C. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective.  Semin Thromb Hemost. 2011;  37 (8) 885-896
  • 2 Jezovnik M K, Poredos P, Stalc M. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis.  J Atheroscler Thromb. 2010;  17 (11) 1190-1198
  • 3 Prandoni P, Bilora F, Marchiori A et al.. An association between atherosclerosis and venous thrombosis.  N Engl J Med. 2003;  348 (15) 1435-1441
  • 4 Jezovnik M K, Poredos P, Lusa L. Idiopathic venous thrombosis is associated with preclinical atherosclerosis.  J Atheroscler Thromb. 2010;  17 (3) 304-311
  • 5 Prandoni P, Ghirarduzzi A, Prins M H et al.. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis.  J Thromb Haemost. 2006;  4 (9) 1891-1896
  • 6 Ageno W, Dentali F. Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.  Thromb Haemost. 2008;  100 (2) 181-183
  • 7 Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis.  Circulation. 2008;  117 (1) 93-102
  • 8 Goldhaber S Z, Savage D D, Garrison R J et al.. Risk factors for pulmonary embolism. The Framingham Study.  Am J Med. 1983;  74 (6) 1023-1028
  • 9 Goldhaber S Z, Grodstein F, Stampfer M J et al.. A prospective study of risk factors for pulmonary embolism in women.  JAMA. 1997;  277 (8) 642-645
  • 10 Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis.  Thromb Res. 1997;  88 (1) 67-73
  • 11 Nowak-Göttl U, Junker R, Hartmeier M et al.. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood.  Circulation. 1999;  100 (7) 743-748
  • 12 Ignatescu M, Kostner K, Zorn G et al.. Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension.  Thromb Haemost. 1998;  80 (2) 231-232
  • 13 Lippi G, Brocco G, Manzato F, Guidi G. Relationship between venous thromboembolism and lipid or lipoprotein disorders.  Thromb Res. 1999;  95 (6) 353-354
  • 14 von Depka M, Nowak-Göttl U, Eisert R et al.. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.  Blood. 2000;  96 (10) 3364-3368
  • 15 Lippi G, Bassi A, Brocco G, Manzato F, Marini M, Guidi G. Lipoprotein(a) concentration is not associated with venous thromboembolism in a case control study.  Haematologica. 1999;  84 (8) 726-729
  • 16 McColl M D, Sattar N, Ellison J et al.. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism.  Blood Coagul Fibrinolysis. 2000;  11 (3) 225-229
  • 17 Ray J G, Rosendaal F R. The role of dyslipidemia and statins in venous thromboembolism.  Curr Control Trials Cardiovasc Med. 2001;  2 (4) 165-170
  • 18 Volpato S, Palmieri E, Fellin R, Zuliani G. Acute phase markers are associated with reduced plasma lipid levels in a population of hospitalized elderly patients.  Gerontology. 2000;  46 (1) 22-27
  • 19 Sattar N, Petrie J R, Jaap A J. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction.  Atherosclerosis. 1998;  138 (2) 229-235
  • 20 Cignarella A, Mussoni L, Mannucci L, Ferioli E, Puglisi L, Tremoli E. Platelet activation supports the development of venous thrombosis in hyperlipidemic rats.  Blood Coagul Fibrinolysis. 1998;  9 (1) 47-53
  • 21 Dzeka T N, Derylo B, Arnold JMO. Endothelial function and statins in human veins.  Can J Cardiol. 2000;  16 193F
  • 22 Bladbjerg E M, Marckmann P, Sandström B, Jespersen J. Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet.  Thromb Haemost. 1994;  71 (6) 755-758
  • 23 Scanu A M. Lipoprotein(a). A genetic risk factor for premature coronary heart disease.  JAMA. 1992;  267 (24) 3326-3329
  • 24 Lippi G, Franchini M, Guidi G C. Lipoprotein(a), athero-thrombosis and longevity. A historical paradox finally elucidated?.  Haematologica. 2007;  92 (4) e48
  • 25 Ridker P M, Danielson E, Fonseca F A JUPITER Study Group et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.  N Engl J Med. 2008;  359 (21) 2195-2207
  • 26 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 (9326) 7-22
  • 27 Undas A, Brummel-Ziedins K E, Mann K G. Statins and blood coagulation.  Arterioscler Thromb Vasc Biol. 2005;  25 (2) 287-294
  • 28 Herrington D M, Vittinghoff E, Lin F HERS Study Group et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).  Circulation. 2002;  105 (25) 2962-2967
  • 29 Ramcharan A S, Van Stralen K J, Snoep J D, Mantel-Teeuwisse A K, Rosendaal F R, Doggen C J. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.  J Thromb Haemost. 2009;  7 (4) 514-520
  • 30 Sørensen H T, Horvath-Puho E, Søgaard K K et al.. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study.  J Thromb Haemost. 2009;  7 (4) 521-528
  • 31 Ray J G, Mamdani M, Tsuyuki R T, Anderson D R, Yeo E L, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis.  Arch Intern Med. 2001;  161 (11) 1405-1410
  • 32 Smeeth L, Douglas I, Hall A J, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials.  Br J Clin Pharmacol. 2009;  67 (1) 99-109
  • 33 Glynn R J, Danielson E, Fonseca F A et al.. A randomized trial of rosuvastatin in the prevention of venous thromboembolism.  N Engl J Med. 2009;  360 (18) 1851-1861
  • 34 Agarwal V, Phung O J, Tongbram V, Bhardwaj A, Coleman C I. Statin use and the prevention of venous thromboembolism: a meta-analysis.  Int J Clin Pract. 2010;  64 (10) 1375-1383
  • 35 Squizzato A, Galli M, Romualdi E et al.. Statins, fibrates, and venous thromboembolism: a meta-analysis.  Eur Heart J. 2010;  31 (10) 1248-1256
  • 36 Lacut K, Le Gal G, Abalain J H, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?.  Thromb Res. 2008;  122 (3) 314-319
  • 37 Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis.  Am J Med. 2008;  121 (10, Suppl 1) S21-S31
  • 38 Jezovnik M K, Poredos P. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction.  Int Angiol. 2010;  29 (3) 226-231
  • 39 Lippi G, Favaloro E J, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association?.  Clin Chem Lab Med. 2010;  48 (12) 1693-1701
  • 40 Ray K K, Cannon C P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?.  Am J Cardiol. 2005;  96 (5A) 54F-60F
  • 41 Albert M A, Danielson E, Rifai N, Ridker P M. PRINCE Investigators . Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.  JAMA. 2001;  286 (1) 64-70
  • 42 Jezovnik M K, Poredos P, Stalc M. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis.  J Atheroscler Thromb. 2010;  17 (11) 1190-1198
  • 43 Spring S, Simon R, van der Loo B et al.. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.  Thromb Haemost. 2008;  99 (1) 182-189
  • 44 Yang Z, Kozai T, van der Loo B et al.. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins.  J Am Coll Cardiol. 2000;  36 (5) 1691-1697
  • 45 Ali F Y, Armstrong P C, Dhanji A R et al.. Antiplatelet actions of statins and fibrates are mediated by PPARs.  Arterioscler Thromb Vasc Biol. 2009;  29 (5) 706-711
  • 46 Kröger N, Shimoni A, Zagrivnaja M et al.. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.  Blood. 2004;  104 (10) 3361-3363
  • 47 Undas A, Brummel K E, Musial J, Mann K G, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation.  Circulation. 2001;  103 (18) 2248-2253
  • 48 Cortellaro M, Cofrancesco E, Arbustini E et al.. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.  Thromb Haemost. 2002;  88 (1) 41-47
  • 49 Doggen C J, Lemaitre R N, Smith N L, Heckbert S R, Psaty B M. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.  J Thromb Haemost. 2004;  2 (5) 700-701
  • 50 Keech A, Simes R J, Barter P FIELD study investigators et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.  Lancet. 2005;  366 (9500) 1849-1861
  • 51 Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features.  Clin Chem Lab Med. 2010;  48 (6) 749-756

Pavel PoredosM.D. Ph.D. 

Full Professor of Internal Medicine, Department of Vascular Disease, Ljubljana University Medical Centre

Zaloska 7, SI-1000 Ljubljana, Slovenia